Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30
- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD) c ohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg , and 40 mg). - ASC30 oral once-daily tablet also...